Recent updates in the treatment of neurodegenerative disorders using natural compounds
- PMID: 24864161
- PMCID: PMC4017872
- DOI: 10.1155/2014/979730
Recent updates in the treatment of neurodegenerative disorders using natural compounds
Abstract
Neurodegenerative diseases are characterized by protein aggregates and inflammation as well as oxidative stress in the central nervous system (CNS). Multiple biological processes are linked to neurodegenerative diseases such as depletion or insufficient synthesis of neurotransmitters, oxidative stress, abnormal ubiquitination. Furthermore, damaging of blood brain barrier (BBB) in the CNS also leads to various CNS-related diseases. Even though synthetic drugs are used for the management of Alzheimer's disease, Parkinson's disease, autism, and many other chronic illnesses, they are not without side effects. The attentions of researchers have been inclined towards the phytochemicals, many of which have minimal side effects. Phytochemicals are promising therapeutic agents because many phytochemicals have anti-inflammatory, antioxidative as well as anticholinesterase activities. Various drugs of either synthetic or natural origin applied in the treatment of brain disorders need to cross the BBB before they can be used. This paper covers various researches related to phytochemicals used in the management of neurodegenerative disorders.
Figures
Similar articles
-
Nanoparticles: A Hope for the Treatment of Inflammation in CNS.Front Pharmacol. 2021 May 26;12:683935. doi: 10.3389/fphar.2021.683935. eCollection 2021. Front Pharmacol. 2021. PMID: 34122112 Free PMC article. Review.
-
Connection between Systemic Inflammation and Neuroinflammation Underlies Neuroprotective Mechanism of Several Phytochemicals in Neurodegenerative Diseases.Oxid Med Cell Longev. 2018 Oct 8;2018:1972714. doi: 10.1155/2018/1972714. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30402203 Free PMC article. Review.
-
Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).J Drug Deliv. 2011;2011:469679. doi: 10.1155/2011/469679. Epub 2011 Dec 13. J Drug Deliv. 2011. PMID: 22203906 Free PMC article.
-
Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.Eur J Pharm Biopharm. 2020 Apr;149:192-217. doi: 10.1016/j.ejpb.2020.01.005. Epub 2020 Jan 23. Eur J Pharm Biopharm. 2020. PMID: 31982574 Review.
-
Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases.Neural Regen Res. 2022 Aug;17(8):1675-1684. doi: 10.4103/1673-5374.332128. Neural Regen Res. 2022. PMID: 35017414 Free PMC article. Review.
Cited by
-
The Use of Nanocarriers to Enhance the Anti-neuroinflammatory Potential of Dietary Flavonoids in Animal Models of Neurodegenerative Diseases: A Systematic Review.Mini Rev Med Chem. 2024;24(13):1293-1305. doi: 10.2174/1389557523666230907093441. Mini Rev Med Chem. 2024. PMID: 37691188
-
Neuropharmacological Effects of Quercetin: A Literature-Based Review.Front Pharmacol. 2021 Jun 17;12:665031. doi: 10.3389/fphar.2021.665031. eCollection 2021. Front Pharmacol. 2021. PMID: 34220504 Free PMC article. Review.
-
Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae).Molecules. 2017 Jul 14;22(7):1181. doi: 10.3390/molecules22071181. Molecules. 2017. PMID: 28708094 Free PMC article.
-
Neuroprotective Polyphenols: A Modulatory Action on Neurotransmitter Pathways.Curr Neuropharmacol. 2020;18(5):431-445. doi: 10.2174/1570159X18666200106155127. Curr Neuropharmacol. 2020. PMID: 31903883 Free PMC article. Review.
-
Oxidative Stress as a Therapeutic Target in Amyotrophic Lateral Sclerosis: Opportunities and Limitations.Diagnostics (Basel). 2021 Aug 26;11(9):1546. doi: 10.3390/diagnostics11091546. Diagnostics (Basel). 2021. PMID: 34573888 Free PMC article. Review.
References
-
- Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology. 2006;66(2):7–19. - PubMed
-
- Aruoma OI, Bahorun T, Jen L-S. Neuroprotection by bioactive components in medicinal and food plant extracts. Mutation Research. 2003;544(2-3):203–215. - PubMed
-
- Jenner P, Olanow CW. Understanding cell death in Parkinson’s disease. Annals of Neurology. 1998;3(1):72–84. - PubMed
-
- Behl C. Alzheimer’s disease and oxidative stress: implications for novel therapeutic approaches. Progress in Neurobiology. 1999;57(3):301–323. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources